Viatris, Inc.

Is Viatris, Inc. overvalued or undervalued?

As of May 9, 2024, Viatris, Inc. is considered overvalued with a P/E ratio of 38, low returns on equity and capital, and significant underperformance compared to the S&P 500, leading to a valuation grade shift from expensive to risky.

As of 9 May 2024, the valuation grade for Viatris, Inc. has moved from expensive to risky, indicating a shift in perception regarding its market valuation. The company appears to be overvalued, as evidenced by a P/E ratio of 38, which is significantly higher than the peer Walgreens Boots Alliance, Inc. at -14.12. Additionally, Viatris has an EV to EBITDA ratio of 6.47 and a Price to Book Value of 0.67, suggesting that its market price does not adequately reflect its underlying asset value.<BR><BR>In comparison to its peers, Viatris's valuation metrics indicate a concerning position, particularly with a return on equity (ROE) of only 1.75% and a return on capital employed (ROCE) of 2.82%. Furthermore, the company's stock has underperformed relative to the S&P 500 across multiple time frames, with a year-to-date return of -20.80% compared to the S&P 500's 12.22%. This trend reinforces the notion that Viatris is currently overvalued in the market.

Is Viatris, Inc. technically bullish or bearish?

As of August 25, 2025, Viatris, Inc. is in a mildly bearish trend, indicated by daily moving averages and a bearish monthly MACD, while underperforming the S&P 500 with year-to-date and one-year returns of -20.80% and -17.14%, respectively.

As of 25 August 2025, the technical trend for Viatris, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages and a bearish monthly MACD. Weekly indicators show mixed signals with the MACD and KST bullish, while the Bollinger Bands indicate a mildly bullish stance. However, the overall weakness is reflected in the Dow Theory and OBV, both showing mildly bearish trends. <BR><BR>In terms of performance, Viatris has underperformed the S&P 500 across multiple periods, with a year-to-date return of -20.80% compared to the S&P 500's 12.22%, and a 1-year return of -17.14% against the S&P 500's 17.14%.

How big is Viatris, Inc.?

As of Jun 18, Viatris, Inc. has a market capitalization of $10.50 billion, with recent net sales of $14.26 billion and a net profit of -$3.79 billion.

Market Cap: As of Jun 18, Viatris, Inc. has a market capitalization of 10,496.93 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Viatris, Inc. reported net sales of 14,264.10 million and a net profit of -3,790.10 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 18,635.50 million, while total assets were reported at 41,500.90 million.

What does Viatris, Inc. do?

Viatris, Inc. is a mid-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $3.24 billion and a net profit of -$3.04 billion. Key metrics include a P/E ratio of 38.00, a dividend yield of 123.82%, and a market cap of approximately $10.5 billion.

Overview: <BR>Viatris, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3,244 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3,042 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 10,496.93 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 38.00 <BR>Dividend Yield: 123.82% <BR>Debt Equity: 0.86 <BR>Return on Equity: 1.75% <BR>Price to Book: 0.67 <BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Viatris, Inc.?